Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Sell
44
RAPT Quote, Financials, Valuation and Earnings
Last price:
$34.00
Seasonality move
:
-10.23%
Day range:
$31.73 - $34.59
52-week range:
$5.67 - $42.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
54.16x
P/B ratio:
3.61x
Volume:
384.7K
Avg. volume:
399.1K
1-year change:
382.67%
Market cap:
$549.3M
Revenue:
--
EPS (TTM):
-$10.51
Analysts' Opinion
-
Consensus RatingRapt Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $65.00, Rapt Therapeutics, Inc. has an estimated upside of 95.7% from its current price of $34.03.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $56.00 representing 100% downside risk from its current price of $34.03.
Fair Value
-
According to the consensus of 7 analysts, Rapt Therapeutics, Inc. has 95.7% upside to fair value with a price target of $65.00 per share.
RAPT vs. S&P 500
-
Over the past 5 trading days, Rapt Therapeutics, Inc. has underperformed the S&P 500 by -3.96% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Rapt Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Rapt Therapeutics, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Rapt Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Rapt Therapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Rapt Therapeutics, Inc. reported earnings per share of -$0.65.
Enterprise value:
394.6M
EV / Invested capital:
2.55x
Price / LTM sales:
54.16x
EV / EBIT:
--
EV / Revenue:
3.48x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-4.55x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$3.9M
Return On Assets:
-59.99%
Net Income Margin (TTM):
--
Return On Equity:
-67.79%
Return On Invested Capital:
-66.16%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$3.4M | -$1.2M | -$3.9M | -$297K | -$200K | |
| Operating Income | -$118.3M | -$114.9M | -$112.6M | -$19.8M | -$19.4M | |
| EBITDA | -$114.9M | -$113.6M | -$108.7M | -$19.5M | -$19.2M | |
| Diluted EPS | -$2.89 | -$2.78 | -$10.51 | -$0.47 | -$0.65 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $214.5M | $197.9M | $187.1M | $102.6M | $161M | |
| Total Assets | $217.5M | $209.5M | $199.7M | $108.5M | $165.7M | |
| Current Liabilities | $12.7M | $13.9M | $21.8M | $10.4M | $13.4M | |
| Total Liabilities | $15.6M | $20.2M | $26.9M | $13M | $13.8M | |
| Total Equity | $201.9M | $189.3M | $172.8M | $95.5M | $152M | |
| Total Debt | -- | $6.3M | $5.1M | $2.6M | $387K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$92.1M | -$100.6M | -$86.6M | -$17.6M | -$12.5M | |
| Cash From Investing | $42.2M | $74.2M | -$56.7M | $18.4M | $8.5M | |
| Cash From Financing | $76.3M | $10.2M | $143.3M | -- | $36K | |
| Free Cash Flow | -$93.3M | -$100.8M | -$86.7M | -$17.6M | -$12.5M | |
RAPT
Sector
Market Cap
$549.3M
$28M
Price % of 52-Week High
78.35%
51.86%
Dividend Yield
0%
0%
Shareholder Yield
-33.45%
-1.4%
1-Year Price Total Return
356.25%
-19%
Beta (5-Year)
0.428
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$35.08
200-day SMA
Buy
Level
$15.73
Bollinger Bands (100)
Buy
Level
14.04 - 31.9
Chaikin Money Flow
Sell
Level
-5.7M
20-day SMA
Buy
Level
$32.41
Relative Strength Index (RSI14)
Buy
Level
55.95
ADX Line
Buy
Level
29.17
Williams %R
Neutral
Level
-53.9691
50-day SMA
Buy
Level
$30.48
MACD (12, 26)
Buy
Level
1.66
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
23.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.0337)
Sell
CA Score
(Annual)
Level (-1.9882)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (4.4172)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, RAPT has received 6 Buy ratings 1 Hold ratings, and 0 Sell ratings. The RAPT average analyst price target in the past 3 months is $65.00.
-
Where Will Rapt Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Rapt Therapeutics, Inc. share price will rise to $65.00 per share over the next 12 months.
-
What Do Analysts Say About Rapt Therapeutics, Inc.?
Analysts are divided on their view about Rapt Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Rapt Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $56.00.
-
What Is Rapt Therapeutics, Inc.'s Price Target?
The price target for Rapt Therapeutics, Inc. over the next 1-year time period is forecast to be $65.00 according to 7 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is RAPT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Rapt Therapeutics, Inc. is a Buy. 6 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RAPT?
You can purchase shares of Rapt Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Rapt Therapeutics, Inc. shares.
-
What Is The Rapt Therapeutics, Inc. Share Price Today?
Rapt Therapeutics, Inc. was last trading at $34.00 per share. This represents the most recent stock quote for Rapt Therapeutics, Inc.. Yesterday, Rapt Therapeutics, Inc. closed at $34.03 per share.
-
How To Buy Rapt Therapeutics, Inc. Stock Online?
In order to purchase Rapt Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get RAPT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RAPT
Sector
P/E ratio
--
24.31x
PEG ratio
-0.01x
-0.01x
P/B ratio
3.61x
1.83x
Price / LTM sales
54.16x
1.60x
Growth Metrics
RAPT
Sector
Revenue growth
--
4.6%
Earnings growth
-37.61%
10.88%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.85
-$0.20
Profitability
RAPT
Sector
Profitability FY 2024
-$3.5M
$3.5M
Return on invested capital
-66.16%
-31.66%
Return on assets
-59.99%
-27.84%
Return on equity
-67.79%
-37.28%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
5
Balance Sheet
RAPT
Sector
Total cash
$157.3M
$26.8M
Short term investments
$61.3M
$26M
Total assets
$240.3M
$78.7M
Long term debt
$387K
$3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
39
SMX alert for Dec 17
SMX (Security Matters) Plc [SMX] is down 18.2% over the past day.
Sell
33
ZBIO alert for Dec 17
Zenas BioPharma, Inc. [ZBIO] is up 13.35% over the past day.
Buy
75
AFRM alert for Dec 17
Affirm Holdings, Inc. [AFRM] is up 11.77% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
